LifePlan Financial Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

LifePlan Financial Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$0	Buy	+2	New	+$284	﹤0.01%	570

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

LifePlan Financial Group's ALNY Position: Q3 2020 in Review

LifePlan Financial Group opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2020: 2 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #570 among its holdings.

356 funds tracked by Wall St. Rank hold ALNY as of Q3 2020.

LifePlan Financial Group held 2 shares of Alnylam Pharmaceuticals worth $0 as of Q3 2020.
Alnylam Pharmaceuticals was a new LifePlan Financial Group position in Q3 2020.
Alnylam Pharmaceuticals made up ﹤0.01% of LifePlan Financial Group's portfolio in Q3 2020, its #570 holding.
356 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2020.

Based on LifePlan Financial Group's 13F filing for Q3 2020, filed 30 Oct 2020.